Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
À¶Ý®ÊÓƵ
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). Feldman, D. R., Hu, J. S., Patil, S., Reuter, V. E., Srinivas, S., Stadler, W., Costello, B., Milowsky, M. I., Appleman, L., Dorff, T. B., Bromberg, M., Joseph, G., Funt, S., Bajorin, D. F., Bosl, G. J., Quinn, D. I., Motzer, R. J. AMER SOC CLINICAL ONCOLOGY. 2019View details for
View details for